NCT01582997View on ClinicalTrials.gov

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 11, 2012

Primary Completion Date

August 1, 2014

Study Completion Date

April 16, 2015

Conditions
Cancer
Interventions
DRUG

GSK2118436

Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.

Trial Locations (2)

411-8777

GSK Investigational Site, Shizuoka

104-0045

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01582997 - A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors | Biotech Hunter | Biotech Hunter